by John A. Jenkins | Jan 8, 2026 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: Growing Scrutiny of Drug Safety and Enforcement As GLP-1 weight-loss drugs surge in popularity, major news organizations are pressing the Food and Drug Administration for internal records that reveal what regulators knew about reports of dangers...
by John A. Jenkins | Dec 10, 2025 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: The Investigative Outlet Gets Active at the FDA Capitol Forum may be one of the more under-the-radar journalistic enterprises in Washington, but recently it was easily the most active when it came to filing FOIA requests with the Food and Drug...
by Randy Miller | Aug 21, 2025 | FOIA, Pharmaceuticals, Politics
FOIAengine: Maker of Elevidys Targeted by 91 FOIA Requests in 19 Months As biotech firm Sarepta Therapeutics (NASD: SRPT) battles patient deaths, regulatory action, and a cratering stock price, its dealings with the Food and Drug Administration are being monitored...
by Randy Miller | Apr 23, 2025 | FDA, FOIA, Hedge Funds, Pharmaceuticals
FOIAengine: Questions Seek Adverse Reports about Carvykti According to a new PoliScio Analytics analysis of early 2025 Freedom of Information Act requests, investment firm Point72 has launched a significant FOIA-driven investigation into Johnson &...
by John A. Jenkins | Apr 9, 2025 | FDA, FOIA, Medical Devices, Pharmaceuticals
FOIAengine: Revolving Door Hits Pfizer on the Way Out The revolving door between the Food and Drug Administration and the pharmaceutical industry took another fast spin when Pfizer announced that Patrizia Cavazzoni would be returning to the company as its chief...
by John A. Jenkins | Jan 8, 2025 | FDA, FOIA, Pharmaceuticals
FOIAengine: How Lilly, Novo Nordisk, Others Use FOIA Welcome to 2025. At PoliScio Analytics, we logged 45,720 federal FOIA requests into our FOIAengine database during the past 12 months. But one subject, more than most others, dominated in hundreds of requests...
